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men classified as unlikely to be, uncertain to be, or likely
to be vitamin B12 deficient (Table 1A). HoloTC was
significantly (P 0.01) lower in the group of vegan men
unlikely to have vitamin B12 deficiency compared with
omnivores, whereas this was not the case for B12 (P 
0.30; Table 1A).
Finally we examined whether holoTC might replace
combined testing with B12, MMA, and tHcy. In this
analysis, individuals were classified as likely to have
vitamin B12 deficiency if at least two of three tests were
outside the cutoff limits (B12 120 ng/L, MMA 0.75
mol/L, tHcy 15 mol/L; n  56) or not (n  139; all
others). The diagnostic accuracy of holoTC was then
assessed by ROC curve analysis (Fig. 1B). The areas under
the ROC curves were 0.91 (95% CI, 0.87–0.95) for all
individuals, 0.88 (95% CI, 0.82–0.95) for vegan men re-
cruited from the EPIC study, and 0.92 (95% CI, 0.85–0.99)
for the men recruited from the London Vegan Society.
We also compared holoTC and the other three markers
in omnivores and in vegan men classified as unlikely to
be, uncertain to be, or likely to be vitamin B12 deficient
based on test results for B12, MMA, and tHcy (Table 1B).
HoloTC was significantly lower (P  0.017) in the vegan
men who were unlikely to be vitamin B12 deficient com-
pared with the omnivores, whereas no significant differ-
ence was observed for the other three measures: B12 (P 
0.49), MMA (P  0.37), and tHcy (P  0.47).
Each of the laboratory tests used for diagnosis of
vitamin B12 deficiency has its weaknesses. The metabolites
MMA and tHcy are influenced by kidney function
(10, 11), and tHcy also depends on the folate status of the
patient. B12 is influenced by the concentration of the
binding proteins of vitamin B12 and is increased in pa-
tients with myeloproliferative diseases (12 ).
Our data are consistent with an early decrease of
holoTC in vitamin B12 deficiency in vegans and further
suggest that holoTC might replace combined testing with
B12, MMA, and tHcy in this population group. If holoTC
is used as the primary screening test, we suggest no
further testing for patients with holoTC 50 pmol/L
(unlikely to suffer from vitamin B12 deficiency) and ho-
loTC 25 pmol/L (likely to suffer from vitamin B12
deficiency). For patients with holoTC between 25 and 50
pmol/L, we would suggest further testing with one of the
metabolic markers.
Further studies are needed to evaluate the validity of
holoTC in other patient groups, especially those with con-
ditions likely to influence markers of vitamin B12 deficiency.
Measurement of holoTC may be of particular value in
identifying vitamin B12 deficiency in patients with kidney
malfunction, in whom the metabolites may show falsely
increased values (10, 11), and in patients with myelopro-
liferative diseases, in whom the concentration of B12 may
be falsely increased (12 ). We conclude that holoTC is a
promising indicator of vitamin B12 deficiency.
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UDP-glucuronosyltransferase 1A1 (UGT1A1) is the key
enzyme for bilirubin conjugation. Defects in this enzyme
can cause a nonhemolytic unconjugated hyperbiliru-
binemia, such as Crigler–Najjar syndrome type 1 (CN1)
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and 2 (CN2) and Gilbert syndrome (GS). In 1991, the
cDNA of the human UGT1A1 gene was cloned, and this
led to the identification of genetic defects in patients
with CN1, CN2, and GS (1–3). It was shown that homozy-
gous or compound heterozygous mutations of the
UGT1A1 gene can lead to these inheritable unconjugated
hyperbilirubinemias, and 30 variants have been identi-
fied (4, 5).
In GS, a TATAA box variant [A(TA)6TAAA(TA)7TAA]
in the promoter region of the UGT1A1 gene has been
reported in Caucasian populations, and several polymor-
phisms in the coding region, including 211GA (G71R),
have been reported to have similar associations with GS
in Japanese populations (6–8). Recently, Sugatani et al.
(9 ) identified a T-to-G substitution in the phenobarbital-
responsive enhancer module 3279 bp upstream from the
UGT1A1 gene. They suggested that the 3279TG poly-
morphism could be another risk factor for the develop-
ment of mild hyperbilirubinemia
Presumably, different combinations of the polymor-
phisms (haplotypes) in the UGT1A1 gene associated with
GS or mild hyperbilirubinemia might produce a variety of
serum total bilirubin (T-Bil) concentrations. Because these
polymorphisms in the UGT1A1 gene lie in a relatively
small region (Fig. 1A), a certain extent of linkage disequi-
librium (LD) among these polymorphisms is expected.
Therefore, haplotype analysis is more reasonable than
association analysis using any single polymorphism to
reveal the genetic background of an increased serum T-Bil
concentration. We analyzed the haplotype structure of the
UGT1A1 gene and investigated its relationship to the
serum T-Bil concentration in healthy Korean males.
The study participants were 324 healthy Korean males
[mean (SD) age, 49.8 (5.4) years] randomly selected from
the registry for routine health checks at Samsung Medical
Center in Seoul, Korea. We restricted the study partici-
pants to males because the prevalence of unconjugated
hyperbilirubinemia is higher in men than in women
because of the lower rate of daily bilirubin production or
other unidentified factors in females (10, 11) and thus the
genetic influence on the bilirubin concentration might be
more evident in men. None had a history of hepatic or
hematologic disorders such as anemia, excessive alcohol
intake, or chronic use of medications or narcotics. In-
formed consent was obtained from all participants, and
the Institutional Review Board of the Samsung Medical
Center approved the study protocol. Serum samples were
collected from each participant in the morning after
overnight fasting. The serum T-Bil concentration was
measured by the diazo method (Daiichi Pure Chemicals)
with the Hitachi 747 system (Hitachi) at least twice with a
1-month interval to provide a mean value for each
participant. The mean values were used in all statistical
analyses.
Two promoter regions containing the 3279TG poly-
morphism and the TATAA box, and a part of exon 1
containing the 211GA polymorphism of the UGT1A1
gene were amplified and sequenced with use of appro-
priate primers, as given in the Data Supplement that
accompanies the online version of this Technical Brief
(available at http://www.clinchem.org/content/vol49/
issue12/). The differences in the serum T-Bil concentra-
tion among the subgroups according to the UGT1A1
alleles or haplotypes were tested by ANOVA. The influ-
ence of smoking status, polymorphisms, and haplotypes
of the UGT1A1 gene on serum T-Bil was also estimated by
the GLM procedure incorporated in the SAS System for
Windows (SAS Institute Inc.). The Hardy–Weinberg equi-
librium was tested with Arlequin software (12 ). Multisite
haplotypes and their frequencies were estimated with use
of SAS Genetics software (SAS Institute Inc.), and the
assignment of haplotypes to each individual was per-
formed with the PHASE program (13 ). Pairwise LD was
estimated as D, D, and r2 (14 ). These LD coefficients were
calculated with use of the SAS Genetics software.
The mean (SD) serum T-Bil concentration in the total
group of participants was 16.3 (5.9) mol/L [0.95 (0.34)
mg/dL]. When we investigated the association of smok-
ing with serum T-Bil concentrations, we observed a sig-
nificant difference among groups by smoking status (P 
0.0058, ANOVA). Current smokers had lower serum T-Bil
concentrations [14.3 (5.3) mol/L; n  71] compared with
Fig. 1. Schematic presentation of the UGT1A1 gene (A), and
LD coefficients (B).
(A), exact sizes of exons (open boxes) and introns are based on the
Ensenmbl transcript ENST00000330771 (http://www.ensembl.
org). Locations of three common polymorphisms are indicated by
arrows. (B), Lewontin’s coefficient (D) and correlation coefficient
(r2) between each pair of the three polymorphisms.
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never smokers [17.9 (6.6) mol/L; n  45], and former
smokers had serum T-Bil concentrations [16.8 (5.8)
mol/L; n  155] between those of current smokers and
never smokers. Smoking status was estimated to explain
3.8% of the variation in serum T-Bil concentrations.
The genotype frequencies of all three polymorphisms
were in Hardy–Weinberg equilibrium, and the frequen-
cies of the 3279G, (TA)7, and 211A alleles were calcu-
lated as 0.267, 0.127, and 0.213, respectively. As shown in
the table in the online Data Supplement, the mean serum
T-Bil concentrations in homozygous carriers of the
3279G, (TA)7, or 211A allele were significantly higher
than those in heterozygous carriers or homozygous car-
riers of wild-type alleles (P 0.0001). Among the three
polymorphisms, homozygous carriers of (TA)7 showed
the highest mean serum T-Bil concentration [33.2 (4.1)
mol/L], followed by homozygous carriers of 211A [24.2
(8.3) mol/L] and 3279G [23.7 (6.2) mol/L]. The
variabilities in serum T-Bil explained by the 3279TG,
(TA)6/7, and 211GA polymorphisms were 15.1%
(P 0.0001), 28.1% (P 0.0001), and 12.9% (P 0.0001),
respectively.
A likelihood ratio test using Arlequin software (12 )
detected significant pairwise LD with D values of 1.0
between all pairs of the three polymorphisms (P 0.0001;
Fig. 1B). The highest correlation was observed between
3279TG and (TA)6/7 polymorphisms (r
2  0.3999; Fig.
1B). Multisite haplotype inference revealed that the par-
ticipants had four of eight possible haplotypes: 3279T-
(TA)6-211G (ht1), 3279T-(TA)6-211A (ht2), 3279G-(TA)6-
211G (ht3), and 3279G-(TA)7-211G (ht4). ht1 was the most
common with an estimated frequency of 0.5201 [95%
confidence interval (CI), 0.4816–0.5586], followed by ht2
(0.2129; 95% CI, 0.1814–0.2445), ht3 (0.1404; 95% CI,
0.1137–0.1672), and ht4 (0.1265; 95% CI, 0.1009–0.1521).
When the participants were stratified into 10 groups
according to their UGT1A1 haplotypes, we observed
significant differences in the mean serum T-Bil concentra-
tion among the groups (P  0.0001; Table 1). The lowest
concentration was observed in group A [ht1/ht1; 13.1
(3.6) mol/L], whereas the highest concentration was
observed in group J [ht4/ht4; 33.2 (4.1) mol/L]. Ho-
mozygous as well as compound heterozygous carriers of
the variant haplotypes (ht2, ht3, or ht4) had increased
serum T-Bil concentrations compared with homozygous
or heterozygous carriers of the wild haplotype (ht1).
Approximately 61.4% and 53.5% of the variability in
serum T-Bil concentrations could be explained by the
UGT1A1 haplotype with or without consideration of
smoking status, respectively.
Multisite haplotype inference revealed that our study
population had only four of eight possible haplotypes.
The four missing haplotypes, 3279T-(TA)7-211G, 3279T-
(TA)7-211A, 3279G-(TA)6-211A, and 3279G-(TA)7-211A,
suggest that 3279T plus (TA)7 and (TA)7 plus 211A
alleles never exist on the same chromosome, at least in a
Korean population. From the above results, we also
suggest that a transition of G to A at nucleotide 211 in
exon 1 of the UGT1A1 gene would form the ht2 haplotype,
whereas a transversion of T to G at nucleotide 3279 in
the promoter region of the UGT1A1 gene would form the
ht3 haplotype. In addition, ht4 could be the result of an
introduction of an extra (TA) repeat to the ht3.
Disclosure of the molecular genetic basis of reduced
expression of UGT1A1 is important not only for under-
standing the molecular pathophysiology of increased se-
rum T-Bil concentrations in GS but also for predicting
severe toxicity by irinotecan in cancer patients (15, 16). In
addition, increased serum T-Bil concentrations have been
associated with a low risk of coronary artery disease
(17, 18). To reveal the genetic background of an increased
serum T-Bil concentration, haplotype analysis is more
reasonable than association analysis using any single
polymorphism because of tight LD among polymor-
phisms in the UGT1A1 gene.
In summary, we demonstrated that there is complete
LD among three common polymorphisms of the UGT1A1
gene in a male Korean population. In addition, we could
unequivocally construct haplotypes for the UGT1A1 gene,
which were revealed to be significantly associated with
the serum T-Bil concentration. However, there are two
major limitations in the present study. One is that the
study population comprised only Korean males and thus
the results cannot be freely applied to other populations,
and the other is that only three common polymorphisms
were included in the analysis. Nevertheless, to the best of
our knowledge, this is one of the first studies to analyze
the haplotype structure of the UGT1A1 gene including
both promoter and coding regions and to assess the
haplotype–phenotype correlation between the UGT1A1
gene and the serum T-Bil concentration.
This work was supported by National Research Labora-
tory Grants from the Korea Institute of Science & Tech-
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Table 1. Haplotype groups and T-Bil concentrations based
on different combinations of three polymorphisms of the
UGT1A1 gene in 324 healthy Korean males.
Group Haplotypea n (%)
Mean (SD) T-Bilb
mol/L mg/dL
A ht1/ht1 90 (27.8) 13.1 (3.6) 0.76 (0.21)
B ht1/ht2 66 (20.4) 15.5 (3.1) 0.91 (0.18)
C ht2/ht2 18 (5.6) 23.7 (6.2) 1.38 (0.36)
D ht1/ht3 54 (16.7) 13.5 (2.8) 0.79 (0.16)
E ht2/ht3 17 (5.2) 16.9 (3.4) 0.99 (0.20)
F ht1/ht4 37 (11.4) 16.3 (4.5) 0.95 (0.26)
G ht2/ht4 19 (5.9) 24.6 (5.1) 1.44 (0.30)
H ht3/ht3 4 (1.2) 18.8 (1.7) 1.10 (0.10)
I ht3/ht4 12 (3.7) 20.7 (7.3) 1.21 (0.43)
J ht4/ht4 7 (2.2) 33.2 (4.1) 1.94 (0.24)
a ht1, 3279T-(TA)6-211G; ht2, 3279T-(TA)6-211A; ht3, 3279G-(TA)6-211G;
ht4, 3279G-(TA)7-211G.
b There were significant differences in concentrations among the genotype
groups (P 0.0001, ANOVA).
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Competitive binding approaches with use of specific
binding proteins are the most commonly used methods to
measure vitamin B12 in laboratory medicine. Various
binding proteins have been used in these methods, in-
cluding intrinsic factor (IF), pooled human or chicken
serum, transcobalamin (TC), and saliva (1, 2). The most
widely used of these are non-human IF preparations,
usually obtained from hog gastric mucosa. Numerous
problems have been reported with their application, how-
ever, including difficulty of purification, instability on
storage, and variation in the binding capacity connected
with changes in serum protein and vitamin B12 concen-
trations (1, 2). If IF is not highly purified, it may contain
haptocorrins (also called R proteins), which bind not only
vitamin B12 but also related metabolically inactive com-
pounds that may be present in the sample, thereby
causing artificially increased vitamin B12 results (1, 3).
To circumvent the problems associated with nonhuman
IF, we recently expressed human IF in plants and ob-
tained a product free of endogenous vitamin B12 and
contaminating vitamin B12-binding proteins (4 ). In the
current study, we examined the feasibility of using this
recombinant human IF for measurement of vitamin B12
bound to TC.
Human IF was expressed in the recombinant plant
Arabidopsis thaliana and purified as described previously
(4 ). As a first step, recombinant human IF was coupled to
magnetic beads (Dynabeads, M-280 Tosylactivated; DY-
NAL) according to the protocol for ligand-binding appli-
cations as recommended by the manufacturer. The beads
from 1 mL of the standard suspension were washed three
times in 0.2 mol/L phosphate-buffered saline, pH 7.4. The
washed beads were mixed with 1 mL of recombinant
human IF (0.5 g/L) and incubated for 24 h at 37 °C with
gentle and continuous agitation. The beads were precipi-
tated, 1 mol/L Tris (pH 7.5) was added to the pellet, and
the incubation was then continued for 4 h. The treated
beads were then washed five times with 2 mL of 0.05
mol/L Tris (pH 7.5)–0.5 mol/L NaCl and suspended in
this buffer.
Recombinant human IF coupled to magnetic beads was
used for measurement of vitamin B12 in the last step of the
Axis-Shield Holo-TC assay in place of the binding protein
supplied with the assay. This step measures the vitamin
B12 bound to TC trapped by insolubilized antibodies (5 ).
The Axis-Shield Holo-TC assay was used to demonstrate
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